Thymogen Alpha-1 contains a synergistic combination of immune-modulating, bioregulator dipeptides thymogen and immune peptide A2 (Lys-Glu).

Based on clinical trials, published literature, and through use of a new technology called metabolomics (measuring the metabolites of large numbers of chemical reactions), this combination is shown to replace, even outperform, the peptide thymosin alpha-1.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.